BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Sk Holdings Co. Ltd.

Headquarters: Seoul, South Korea
Year Founded: 1987
Status: Public
Industry Sector: Finance
CEO: Tae-Won Choi, PhD; Yong-Ho Jang
Number Of Employees: 4,404
Enterprise Value: $83,373,435,192
PE Ratio: -4.92
Exchange/Ticker 1: KRX:034730
Exchange/Ticker 2: N/A
Latest Market Cap: $5,093,511,662

BioCentury | Mar 1, 2022
Deals

Feb. 28 Quick Takes: Heidelberg shares jump as Huadong takes stake

Plus FDA approves CTI’s pacritinib, Aurinia shares sink, Lexicon submission delayed, priority review for neoadjuvant Opdivo and more
BioCentury | May 8, 2017
Financial News

Aadi raises $23M series A round

BioCentury | Apr 29, 2013
Company News

SK Biopharmaceuticals, SK Chemicals deal

BioCentury | Feb 1, 2010
Clinical News

Comfyde carisbamate regulatory update

BioCentury | Aug 24, 2009
Clinical News

Carisbamate regulatory update

BioCentury | Jul 6, 2009
Finance

2H09 Milestones

BioCentury | May 25, 2009
Company News

Addrenex, SK Holdings deal

BioCentury | Dec 15, 2008
Clinical News

Comfyde carisbamate: Phase III data

BioCentury | Dec 15, 2008
Clinical News

Comfyde carisbamate: Phase III data

BioCentury | Oct 27, 2008
Clinical News

Comfyde carisbamate regulatory update

Items per page:
1 - 10 of 10